Protagonist Therapeutics, Inc (PTGX) › Operating Cash FlowProtagonist Therapeutics, Inc (PTGX) — Operating Cash FlowAnnual figures by period end, from SEC filings.2015-12-31: -$14.38M2016-12-31: -$29.97M2017-12-31: $3.87M2018-12-31: -$49.95M2019-12-31: -$41.53M2020-12-31: -$72.48M2021-12-31: -$107.86M2022-12-31: -$108.14M2023-12-31: -$70.24M2024-12-31: $184.15M2025-12-31: $57.67M$57.67M2015-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31$57.67M-68.7%2026-02-25From 2025-01-012024-12-31$184.15M—2026-02-25From 2024-01-012023-12-31-$70.24M—2026-02-25From 2023-01-012022-12-31-$108.14M—2025-02-21From 2022-01-012021-12-31-$107.86M—2024-02-27From 2021-01-012020-12-31-$72.48M—2023-03-15From 2020-01-012019-12-31-$41.53M—2022-02-28From 2019-01-012018-12-31-$49.95M-1390.0%2021-03-10From 2018-01-012017-12-31$3.87M—2020-03-10From 2017-01-012016-12-31-$29.97M—2019-03-12From 2016-01-012015-12-31-$14.38M—2018-03-07From 2015-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)